(Q36724334)

15 August 2017

1 reference

title

New therapeutic approaches for metastatic thyroid carcinoma (English)

1 reference

15 August 2017

Eric Baudin

1

1 reference

PubMed ID

17267329

15 August 2017

Martin Schlumberger

series ordinal

2

1 reference

15 August 2017

1 February 2007

1 reference

Lancet Oncology Commission

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

2

1 reference

15 August 2017

148-156

1 reference

Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997)

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Increasing incidence of thyroid cancer in the United States, 1973-2002

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Long-term results and prognostic factors in patients with differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Survival and death causes in differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Thyroid-hormone therapy and thyroid cancer: a reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Pattern of nodal metastasis for primary and reoperative thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Gene therapy for thyroid cancer: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Phase II study of celecoxib in metastatic differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

Radiation combined with antiangiogenic and antivascular agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970034-7

7 January 2021

10.1016/S1470-2045(07)70034-7

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17267329